米多君与白蛋白预防等待肝移植的肝硬化患者并发症:一项随机安慰剂对照试验
这项多中心随机双盲安慰剂对照试验纳入196例等待肝移植的肝硬化腹水患者,随机接受米多君(15-30 mg/日)联合白蛋白(40 g/15天)或匹配安慰剂治疗一年。结果显示两组并发症发生概率(p=0.402)和一年死亡率(p=0.527)无显著差异,联合治疗仅轻微抑制血管收缩系统活性。
要点
- 米多君联合白蛋白未降低等待肝移植肝硬化患者的并发症发生概率(p=0.402)。
- 两组一年死亡率无显著差异(p=0.527)。
- 治疗组血浆肾素活性(-4.3 vs 0.1 ng/ml.h,p<0.001)和醛固酮(-38 vs 6 ng/dl,p=0.02)较安慰剂组轻微但显著降低。
核心结论
- 在等待肝移植的肝硬化患者中,本研究剂量的米多君联合白蛋白治疗轻微抑制了血管收缩系统活性,但未能预防肝硬化并发症或改善生存。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验(NCT00839358),纳入196例连续等待肝移植的肝硬化腹水患者。
- 患者随机接受米多君(15-30 mg/日)联合白蛋白(40 g/15天)或匹配安慰剂治疗一年,直至肝移植或从等待名单退出。
主要发现
- 两组随访期间发生肝硬化并发症的概率无显著差异(p=0.402)。
- 两组一年死亡率无显著差异(p=0.527)。
- 与安慰剂组相比,米多君联合白蛋白组第48周较基线的血浆肾素活性(-4.3 vs 0.1 ng/ml.h,p<0.001)和醛固酮(-38 vs 6 ng/dl,p=0.02)轻微但显著降低。
- 血浆去甲肾上腺素仅在第4周轻微下降;动脉压和血浆细胞因子水平均无显著变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with decompensated cirrhosis on the waiting list for liver transplantation (LT) commonly develop complications that may preclude them from reaching LT. Circulatory dysfunction leading to effective arterial hypovolemia and activation of vasoconstrictor systems is a key factor in the pathophysiology of complications of cirrhosis. The aim of this study was to investigate whether treatment with midodrine, an alpha-adrenergic vasoconstrictor, together with intravenous albumin improves circulatory dysfunction and prevents complications of cirrhosis in patients awaiting LT. METHODS: A multicenter, randomized, double-blind, placebo-controlled trial (NCT00839358) was conducted, including 196 consecutive patients with cirrhosis and ascites awaiting LT. Patients were randomly assigned to receive midodrine (15-30 mg/day) and albumin (40 g/15 days) or matching placebos for one year, until LT or drop-off from inclusion on the waiting list. The primary endpoint was incidence of any complication (renal failure, hyponatremia, infections, hepatic encephalopathy or gastrointestinal bleeding). Secondary endpoints were mortality, activity of endogenous vasoconstrictor systems and plasma cytokine levels. RESULTS: There were no significant differences between both groups in the probability of developing complications of cirrhosis during follow-up (p = 0.402) or one-year mortality (p = 0.527). Treatment with midodrine and albumin was associated with a slight but significant decrease in plasma renin activity and aldosterone compared to placebo (renin -4.3 vs. 0.1 ng/ml.h, p < 0.001; aldosterone -38 vs. 6 ng/dl, p = 0.02, at week 48 vs. baseline). Plasma norepinephrine only decreased slightly at week 4. Neither arterial pressure nor plasma cytokine levels changed significantly. CONCLUSIONS: In patients with cirrhosis awaiting LT, treatment with midodrine and albumin, at the doses used in this study, slightly suppressed the activity of vasoconstrictor systems, but did not prevent complications of cirrhosis or improve survival. LAY SUMMARY: Patients with cirrhosis who are on the liver transplant waiting list often develop complications which prevent them from receiving a transplant. Circulatory dysfunction is a key factor behind a number of complications. This study was aimed at investigating whether treating patients with midodrine (a vasoconstrictor) and albumin would improve circulatory dysfunction and prevent complications. This combined treatment, at least at the doses administered in this study, did not prevent the complications of cirrhosis or improve the survival of these patients.
引用
- Solà E, Solé C, Simón-Talero M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol. 2018. PMID: 30138685. doi:10.1016/j.jhep.2018.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。